B+
Bull case
20%
Probability
Target price
$220.00
+17.1% vs current
DVA
DaVitaANYSE / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$160.00
-14.8% vs current
B-
Bear case
30%
Probability
Target price
$130.00
-30.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+35.3
Score
AI commentary
Primary-source evidence is solid, but the setup still looks more like a monitoring story than a fresh upside thesis: outside-news flow is thin, no social aggregate was provided, no current analyst revision set was available, and direct public peer validation is limited beyond Fresenius Medical Care. Those gaps make it hard to validate the stock's premium to the packet's median target after the May 5 earnings release.
RankAlpha Sentiment Codex - 2026-05-16
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-06-30catalystRaised 2026 outlook and aggressive buybacks support near-term EPS framingMedium impact
DaVita's May 5, 2026 earnings release reported Q1 revenue of $3.416 billion, operating income of $482 million, diluted EPS from continuing operations of $2.87, and lifted 2026 adjusted operating income guidance to $2.15-$2.25 billion from $2.085-$2.235 billion while lifting adjusted EPS guidance to $14.10-$15.20 from $13.60-$15.00; the company also repurchased 3.0 million shares in Q1 and another roughly 2.0 million shares through May 5, 2026. [#8-K-2026-05-05]
2026-08-10eventNext operating checkpoint is whether reimbursement gains continue to outpace cost inflationMedium impact
Q1 revenue per treatment rose year over year, helped by normal annual increases including Medicare base rate, but patient care cost per treatment also increased; the next results cycle should show whether pricing and payer/reimbursement mix continue to absorb labor, insurance, and medical supplies inflation. [#10-Q-2026-05-05]
2026-12-31catalystIntegrated kidney care scale remains a strategic offset to mature dialysis growthHigh impact
As of March 31, 2026, DaVita reported about 62,600 patients in risk-based integrated care arrangements representing about $5.4 billion in annualized medical spend, giving the company a longer-duration value-based care lever beyond low-growth core dialysis volumes. [#10-Q-2026-05-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology